G

    Galmed Pharmaceuticals Ltd (GLMD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.12
    -0.04 (-1.08%)

    Market Cap: $4.34M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    70%(26/37)
    Avg Surprise
    +36.14%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-3.12
    Range$-3.12 - $-3.12
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$0.00+100.0%
    7d ago$0.00+100.0%
    Current$-3.12
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    Dec 31, 2026
    EPS Consensus$-5.86
    Range$-5.86 - $-5.86
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-5.86---
    Sep 26EST
    		-$-3.12---
    Jun 26
    		$5.04$-0.38+1426.32%Beat+900.0%
    Mar 26
    		$-0.62$-0.51-21.57%Miss+0.0%
    Dec 25
    		$-0.92$-0.51-80.39%Miss+52.6%
    Sep 25
    		$-0.33$-0.54+38.89%Beat+85.7%
    Jun 25
    		$-0.63$-0.83+24.10%Beat+70.5%
    Mar 25
    		$-0.62$-0.89+30.34%Beat+76.5%
    Dec 24
    		$-1.94N/AN/ABeat-98.0%
    Sep 24
    		$-2.31N/AN/ABeat+19.9%
    Jun 24
    		$-2.13$0.00N/ABeat+81.3%
    Mar 24
    		$-2.64$-3.84+31.25%Beat-142.2%
    Dec 23
    		$-0.98$-0.32-206.25%Miss+94.6%
    Sep 23
    		$-2.88$-3.60+20.00%Beat+92.4%
    Jun 23
    		$-11.40$-4.08-179.41%Miss+57.8%
    Mar 23
    		$-1.09$-1.50+27.33%Beat+98.0%
    Dec 22
    		$-18.00$-25.20+28.57%Beat-5900.0%
    Sep 22
    		$-37.80$-27.90-35.48%Miss+32.3%
    Jun 22
    		$-27.00$-42.75+36.84%Beat+54.5%
    Mar 22
    		$-54.00$-58.80+8.16%Beat+21.1%
    Dec 21
    		$-0.30$-0.30+0.00%Beat+37.5%
    Sep 21
    		$-55.80$-68.40+18.42%Beat+3.1%
    Jun 21
    		$-59.40$-75.60+21.43%Beat-26.9%
    Mar 21
    		$-68.40$-71.10+3.80%Beat-31.0%
    Dec 20
    		$-0.48$-0.36-33.33%Miss-23.1%
    Sep 20
    		$-57.60$-67.80+15.04%Beat-52.4%
    Jun 20
    		$-46.80$-58.32+19.75%Beat-30.0%
    Mar 20
    		$-52.20$-66.00+20.91%Beat-70.6%
    Dec 19
    		$-0.39$-0.34-14.71%Miss-116.7%
    Sep 19
    		$-37.80$-55.03+31.31%Beat-320.0%
    Jun 19
    		$-36.00$-38.83+7.29%Beat-17.6%
    Mar 19
    		$-30.60$-37.29+17.94%Beat+0.0%
    Dec 18
    		$-0.18$-0.13-38.46%Miss+33.3%
    Sep 18
    		$-9.00N/A+64.29%Beat+78.3%
    Jun 18
    		$-30.60$-28.54-7.22%Miss+22.7%
    Mar 18
    		$-30.60$-41.40+26.09%Beat+34.6%
    Dec 17
    		$-0.27$-0.22-22.73%Miss+32.5%
    Sep 17
    		$-41.40$-48.00+13.75%Beat+32.4%
    Jun 17
    		$-39.60$-59.40+33.33%Beat-
    Mar 17
    		$-46.80$-68.85+32.03%Beat-
    Dec 16
    		$-0.40$-0.30-33.33%Miss-
    Sep 16
    		$-61.20$-70.20+12.82%Beat-

    Key Metrics

    Valuation
    P/E Ratio0.16EV/EBITDA0.32x
    Price/FCF-0.41xFCF Yield-246.30%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-72.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio7.71xQuick Ratio7.71x
    Trading Statistics
    Beta0.68Avg Volume102.02K
    52-Week High$5.4552-Week Low$0.41

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.34
    SMA 20$4.42
    SMA 50$4.45
    SMA 200$5.45
    EMA 10$4.28
    EMA 20$4.36
    EMA 50$4.49
    EMA 200$6.05

    MACD

    Line: -0.08Signal: -0.05Hist: -0.03

    ADX

    ADX: 47.5+DI: 9.7-DI: 2.1

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down4.0
    PSAR$1.85

    Bollinger Bands

    Upper Band$4.92
    Lower Band$3.93
    %B Position2229%(Upper)
    Band Width0.19

    RSI (14-Day)

    Neutral
    43.5

    Momentum Oscillators

    Stoch %K74.7
    Stoch %D75.9
    Williams %R-26.9
    ROC (10d)0.3%
    Momentum0.01
    CCI (20d)63.4
    MFI (14d)43.3

    Volatility Measures

    ATR (14d)$2.24(54.4%)
    StdDev (20d)0.25
    Hist Vol67.4%(High)

    Volume Flow

    VWAP$4.10
    OBV424.8M
    AD Line24.2B
    CMF (20d)96.511

    Volume Metrics

    Avg Vol (20d)103.5K
    Vol Ratio0.1x(Low)
    VWMA (20d)$4.33

    Pivot Points

    R3$4.60
    R2$4.43
    R1$4.30
    Pivot Point$4.13
    S1$4.00
    S2$3.83
    S3$3.69

    Advanced Oscillators

    TSI-6.77
    Ultimate Osc73.7
    KST-31.07

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$0$0$0$0$0$0
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/A$74,000$9,000N/A$17,000
    Gross ProfitN/AN/AN/AN/AN/AN/AN/AN/A$-74,000$-9,000N/A$-17,000
    Operating Expenses$2.04M$3.04M$3.04M$2.10M$2.11M$1.26M$1.64M$2.01M$1.22M$1.40M$2.15M$1.47M
    R&D$1.36M$2.10M$2.10M$1.09M$1.06M$634,000$1.07M$738,000$534,000$635,000$1.12M$556,000
    SG&A$684,000$946,000$946,000$1.01M$1.05M$630,000$572,000$1.27M$688,000$766,000$1.03M$912,000
    Operating Income$-2,044,000$-3,042,000$-3,042,000$-2,095,000$-2,109,000$-1,264,000$-1,644,000$-2,011,000$-1,222,000$-1,401,000$-2,151,000$-1,468,000
    Interest Income$0$0$411,000$203,000$140,000$0$0$97,000$103,000$0$0$0
    Interest Expense$0$1.78M$1.78M$0$386,000$448,000$1.56M$0$0$0$0$5,000
    Income Before Tax$-1,910,000$-4,818,000$-4,818,000$-1,892,000$-2,495,000$-1,104,000$-3,209,000$-1,914,000$-1,119,000$-1,275,000$-2,016,000$-1,473,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$-37,812$0$47,586
    Net Income$-1,910,000$-4,818,000$-4,818,000$-1,892,000$-2,495,000$-1,104,000$-3,209,000$-1,914,000$-1,119,000$-1,275,000$-2,016,000$-1,473,000
    EBITDA$-2,044,000$-4,818,000$-3,042,000$-1,892,000$-2,495,000$-1,104,000N/A$-1,914,000$-1,045,000$-1,266,000N/A$-1,460,000
    EBITN/AN/AN/A$-2,095,000N/A$-3,209,000N/AN/A$-1,119,000$-1,275,000N/A$-1,468,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about GLMD

    News

    Galmed (NASDAQ: GLMD) tests new tool to gauge colon tissue in surgery

    Galmed Pharmaceuticals Ltd. (GLMD), through its subsidiary Colospan Ltd., announced successful first-in-human clinical study results for a new intraoperative colon tissue quality assessment platform. The study, involving 32 colorectal cancer patients, demonstrated the technical feasibility of quantitatively measuring colon tissue compliance ex-vivo, with no measurement failures. This new platform aims to provide real-time objective data to surgeons for improved decision-making and risk assessment, complementing Colospan's existing CG-100 intraluminal bypass device.

    Stock Titan•8/20/26•
    Bullish

    Galmed completes feasibility study for colon tissue assessment tech

    Colospan Ltd., a subsidiary of Galmed Pharmaceuticals Ltd., has successfully completed a feasibility study for a new tissue quality assessment platform for colorectal surgery. The study, involving 32 colorectal cancer patients in Israel, demonstrated the feasibility of quantitatively measuring colon tissue compliance using an ex-vivo method, with no technical issues reported. This platform is designed to provide surgeons with real-time information on tissue mechanical properties to aid intraoperative decision-making and complements Colospan's existing CG-100 intraluminal bypass device.

    Investing.com•8/20/26•
    Bullish

    Galmed completes feasibility study for colon tissue assessment tech By Investing.com

    Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) subsidiary Colospan Ltd. has successfully completed a feasibility study for a new tissue quality assessment platform for colorectal surgery. The study, conducted on 32 colorectal cancer patients in Israel, demonstrated the viability of quantitatively measuring colon tissue compliance using an ex-vivo method, with no technical issues reported. This platform, which provides real-time information on tissue mechanical properties, is Colospan's second technology, complementing its FDA Breakthrough Device designated CG-100 intraluminal bypass device.

    Investing.com Nigeria•8/19/26•
    Bullish

    Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

    Galmed Pharmaceuticals Ltd. announced successful first-in-human proof-of-concept clinical study results for Colospan's novel intraoperative tissue assessment technology. The study, involving 32 colorectal cancer patients, demonstrated the feasibility of quantitatively measuring colon tissue quality, establishing a clinical foundation for developing an intraoperative device. This new platform complements Colospan's CG-100 intraluminal bypass device, aiming to provide surgeons with objective, real-time information to aid surgical decision-making and potentially reduce risks like Low Anterior Resection Syndrome (LARS).

    PR Newswire•8/19/26•
    Bullish

    Galmed completes feasibility study for colon tissue assessment tech By Investing.com

    Colospan Ltd., a subsidiary of Galmed Pharmaceuticals Ltd., has successfully completed a feasibility study for a new tissue quality assessment platform for colorectal surgery. This platform aims to provide surgeons with real-time quantitative measurements of colon tissue quality, enhancing intraoperative decision-making. The technology complements Colospan's existing CG-100 intraluminal bypass device.

    Investing.com Australia•8/19/26•
    Bullish

    Frequently Asked Questions About GLMD

    Does GLMD pay dividends?
    Galmed Pharmaceuticals Ltd (GLMD) does not currently pay a regular dividend.
    What is GLMD's P/E ratio?
    Galmed Pharmaceuticals Ltd has a price-to-earnings (P/E) ratio of 0.16.
    What is GLMD's market cap?
    Galmed Pharmaceuticals Ltd (GLMD) has a market capitalization of $4.34M with a current stock price of $4.12.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In